Skip to main
COGT
COGT logo

Cogint (COGT) Stock Forecast & Price Target

Cogint (COGT) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences Inc. is on track for a potentially significant year in 2025, with expectations of becoming an appealing target for mergers and acquisitions, particularly if the outcomes of the APEX and PEAK trials are favorable. The company's valuation has been positively adjusted, reflecting an increased probability of approval for its drug combination treatment in advanced gastrointestinal stromal tumors (GIST), alongside a notable rise in expected market penetration rates. Additionally, the impressive overall response rates observed across multiple clinical trials—including the SUMMIT trial—suggest that the therapy bezuclastinib may have a robust competitive standing in the treatment landscape for various malignancies.

Bears say

Cogent Biosciences is projected to experience a substantial net loss of $2.28 per share for the entirety of 2025, indicating ongoing financial challenges. A number of risks contribute to this negative outlook, including the possibility of adverse clinical data for key drugs, delays in development timelines, and potential setbacks in obtaining regulatory approvals. Additionally, concerns surrounding commercial success and the risk of long-term dilution further exacerbate the company’s financial vulnerabilities.

Cogint (COGT) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogint (COGT) Forecast

Analysts have given Cogint (COGT) a Buy based on their latest research and market trends.

According to 11 analysts, Cogint (COGT) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogint (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.